Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies.
Vir Biotechnology has exclusive rights to the universal PRO-XTEN® masking platform for oncology and infectious disease. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
We believe the success of our colleagues drives the success of our mission. We are committed to creating a company where everyone feels supported and encouraged to give their best.
Vir Bio is seeking a Vice President of Financial Planning & Analysis to lead enterprise‑wide financial planning and serve as a core member of the Company’s strategic and operational leadership. This role is accountable for driving capital allocation, long‑range financial strategy, and performance management across the organization, with direct impact on enterprise value creation and strategic decision‑making.
The VP, FP&A will own the Company’s planning and forecasting architecture, valuation framework, and financial decision support, partnering closely with the executive team, functional leadership, and project teams. This is a highly visible, hands‑on leadership role requiring strong judgment, deep biotech financial expertise, and the ability to translate complexity into clear, actionable recommendations.
This role is based in Vir’s San Francisco headquarters with an expectation of at least three days per week in the office.
WHAT YOU'LL DO- Lead the enterprise FP&A function, establishing short‑ and long‑term financial plans that align capital deployment with the Company’s highest‑value strategic priorities
- Own company‑wide budgeting, forecasting, and long‑range planning processes, with accountability for performance against plan and recommended corrective actions
- Serve as a senior finance business partner to executive leadership, providing financial leadership on clinical development, manufacturing, partnerships, commercial and key strategic initiatives
- Partner with Accounting on collaboration and partnership financials, including quarter‑end activities, external funding applications, reporting, and partner‑facing budget management
- Maintain and continuously refine the Company’s internal valuation and scenario‑modeling framework
- Lead, develop, and scale a high‑performing FP&A team responsible for portfolio investment analysis and strategic financial support for R&D
- Advance financial analytics, reporting, and systems to support executive, Board, investor, and partner decision‑making along with assisting with internal and business development valuations
- Design and implement process and reporting enhancements that improve transparency, discipline, and decision quality
- Bachelor’s degree in finance, accounting, or a related discipline, with fifteen or more years of progressive finance leadership experience
- MBA and/or CPA, or equivalent advanced credentials strongly preferred
- Deep experience supporting biotech or pharmaceutical R&D organizations, including development economics and portfolio decision‑making
- Demonstrated expertise in valuation, scenario modeling, and capital allocation in complex and uncertain environments
- Commercial financial planning expertise in the Biotech or Pharma industry
- Proven executive leadership skills, including building and leading teams, influencing senior stakeholders, and partnering cross‑functionally
- Strong systems orientation with experience operating sophisticated planning, forecasting, or ERP platforms
- Sound knowledge of US GAAP, internal controls, and SOX‑compliant environments
The expected salary range for this position is $300,000 to $350,000. Actual pay will be determined based on experience, qualifications, geographic location, and other job-related factors.
Vir Biotechnology's compensation and benefits are aligned with the current market and commensurate with the person’s experience and qualifications. All full-time employees receive a package that includes compensation, bonus and equity as well as many other Vir Biotechnology benefits and perks such as health and welfare benefit plans, non-accrual paid time off, company shut down for holidays, commuter benefits, 401K match and lunch each day in the office.
Applicants must currently be authorized to work for any employer in the U.S. We are unable to sponsor or take over sponsorship of an employment Visa at this time.
All employment decisions at Vir Biotechnology are based on legitimate, non-discriminatory business requirements, job duties and individual qualifications. Employment decisions are made without regard to any legally protected characteristics.
This commitment extends to all management practices and decisions, including recruitment and hiring, compensation, appraisal systems, promotions, training and career development programs. Vir Biotechnology also strongly commits to providing employees with a work environment free of unlawful conduct or harassment.
Vir Biotechnology Human Resources leads recruitment and employment for Vir Biotechnology. Unsolicited resumes sent to the company from recruiters do not constitute any type of relationship between the recruiter and Vir Biotechnology and do not obligate us to pay fees should we hire from those resumes. We ask that external recruiters and/or agencies not contact or present candidates directly to our hiring manager or employees.
For hires based in the United States, Vir Biotechnology, participates in E-Verify.
Candidate Privacy Notice
Similar Jobs
What you need to know about the San Francisco Tech Scene
Key Facts About San Francisco Tech
- Number of Tech Workers: 365,500; 13.9% of overall workforce (2024 CompTIA survey)
- Major Tech Employers: Google, Apple, Salesforce, Meta
- Key Industries: Artificial intelligence, cloud computing, fintech, consumer technology, software
- Funding Landscape: $50.5 billion in venture capital funding in 2024 (Pitchbook)
- Notable Investors: Sequoia Capital, Andreessen Horowitz, Bessemer Venture Partners, Greylock Partners, Khosla Ventures, Kleiner Perkins
- Research Centers and Universities: Stanford University; University of California, Berkeley; University of San Francisco; Santa Clara University; Ames Research Center; Center for AI Safety; California Institute for Regenerative Medicine
